Elocalcitol - Adge Pharmaceuticals
Alternative Names: RO-269228Latest Information Update: 28 Apr 2022
At a glance
- Originator Roche Palo Alto LLC
- Developer Adge Pharmaceuticals
- Class Dihydroxycholecalciferols; Small molecules; Urologics; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Osteogenesis imperfecta; Rett syndrome
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 25 Apr 2022 Elocalcitol licensed to Cyan Bio in South Korea, Greater China, Japan, India and Southeast Asian countries for the treatment of Rett syndrome and osteogenesis imperfecta
- 23 Mar 2022 Adge Pharmaceuticals and Roche entered into a licensing agreement to develop elocalcitol for the treatment of Rett syndrome and Osteogenesis imperfecta
- 23 Mar 2022 Preclinical trials in Osteogenesis imperfecta in USA (PO)